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Medication Management in Geriatrics | Overview of Beers 
Criteria 2015
Dr. Anum Adil , Trainee Pharmacist
On 8th October, updated American Geriatrics Society (AGS) Beers drug list was 
published. The AGS Beers Criteria 
highlights the high risk medications 
along with potentially harmful 
drug–disease interactions in the 
elderly.  This  updated l is t  is 
applicable to all the older adults 
with the exception of those who are in palliative and hospice care. Healthcare 
professionals should use this list to reduce the inappropriate drug prescribing 
trends among the geriatric.  However, it must not be the only source to consider 
while suggesting medications to one of the most vulnerable group.
“Non- Pharmacological 
approaches are suggested as 
primary alternate to medicines”
Table 1. Alternatives for Medications Included in the High-Risk Medications in 
the Elderly Measure
THERAPEUTIC 
CLASS
HIGH-RISK 
MEDICATIONS**
ALTERNATIVES
ANTICHOLINERGIC
First-Generation 
Antihistamine
Parkinson 
Disease
Chlorpheniramine, 
Clemastine, 
Diphenhydramine, 
Doxylamine, Hydroxyzine, 
Promethazine
Trihexyphenidyl
Intranasal normal saline  and OTC 
steroids (eg; uticasone , 
beclomethasone) Second-generation 
antihistamine (e.g., cetirizine, 
fexofenadine)
Carbidopa/levodopa 
CARDIOVASCULAR
Alpha Agonists, 
Central
Other
Antiplatelet
Methyldopa
Disopyramide
Nifedipine- Immediate 
Release (N/A at AKUH)
Dipyridamole
(oral immediate release)
(N/A at AKUH)
Thiazide-type diuretic, ACEI, ARB, 
long-acting dihydropyridine CCB  
preferred
Atrial brillation: 
For rate control non-dihydropyridine 
CCB (e.g., diltiazem), beta-blocker 
for rate control Long acting 
dihydropyridine CCB (e.g., 
amlodipine) should be preferred
Antithrombotic therapy for the 
secondary prevention of 
noncardioembolic stroke, 
Clopidogrel, aspirin 25 mg with 
extended-release dipyridamole 
200 mg
Medication Management in Geriatrics | 
Overview of Beers Criteria 2015   1
Zika Virus Disease (ZVD) – An Emerging 
Culprit     3
Emerging Avenues for Botulinium 
Toxin Therapy    4
Novel Treatment Approach of 
Pancreatic Cancer    4
FDA Podcast 2015    5
Extra Care is Needed Because Warfarin is 
High - Alert Medicine   6
Reporting of ADR    7
ADR Trends of 2015 at AKUH    8
CENTRAL NERVOUS SYSTEM
Amitriptyline, Clomipramine, 
Imipramine
Phenobarbital
Ergot mesylates, Isoxsuprine 
(N/A at AKUH)
Zolpidem
Thioridazine
Chloral hydrate
For depression—SSRI (except paroxetine), SNRI, 
bupropion. For neuropathic pain—SNRI, gabapentin, 
capsaicin topical, pregabalin, lidocaine patch.
For epilepsy-other anticonvulsants (e.g., lamotrigine, 
levetiracetam)
Acetylcholinesterase inhibitors, memantine, 
Vitamin E
None
Schizophrenia: Non-anticholinergic antipsychotic 
(not chlorpromazine, olanzapine, triuoperazine)
For Anxiety- buspirone , SSRI, SNRI
Tertiary, Tricyclic 
Antidepressant
Barbiturate
Vasodilator
Non-benzodiazepine 
Hypnotics
Other
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THERAPEUTIC CLASS HIGH-RISK MEDICATIONS** ALTERNATIVES
ENDOCRINE SYSTEM
Use of vaginal estrogen is acceptable for treatment of 
dyspareunia and vulvovaginitis. Vasomotor 
symptoms—SSRI, SNRI, gabapentin
Short-acting sulfonylureas (glipizide, gliclazide), 
metformin
Levothyroxine
Conjugated estrogen, Esteried 
estrogen, Estradiol(Oral Or Patch)
Glyburide (Long-Duration)
Desiccated thyroid
Estrogens With Or 
Without Progestins 
Sulfonylureas
Other
PAIN MEDICATION
Acetaminophen, nonacetylated salicylate (e.g., 
salsalate), propionic acid derivatives 
(e.g., ibuprofen, naproxen) if no heart failure or 
eGFR >30 mL/min and given with PPI for 
gastro-protection
Acute Pain: Tramadol, morphine, oxycodone 
immediate release with acetaminophen.. 
Chronic Pain: —all the above; avoid 
sustained-release dosage forms in 
opioid-naïve individuals 
Orphenadrine
Acute mild or moderate pain
Indomethacin,Ketorolac 
Chronic mild or moderate pain
Pethidine
Skeletal Muscle 
Relaxants
Specic NSAIDs
Opioids
Table 2. Alternatives to Medications Included in the Potentially Harmful Drug-Disease Interactions in the Elderly
DISEASES & POTENTIALLY 
HARMFUL DRUGS
FOR FALLS
ALTERNATIVES
For new-onset epilepsy—newer agents preferred (e.g., lamotrigine, levetiracetam 
For anxiety and depression—buspirone, SNRI 
Anticonvulsants
Benzodiazepines, Non-
Benzodiazepines hypnotics, 
Tricyclic antidepressants , SSRIs
Antipsychotics For Delirium-  Short-term use of antipsychotics (e.g., haloperidol, quetiapine) 
should be restricted to individuals who are considered a risk to themselves or 
others and in whom verbal and nonverbal de-escalation techniques are ineffective 
or inappropriate
SYMPTOMS TREATMENT PREVENTION
Symptoms are related to arbovirus 
infections (like dengue, chikungunya), 
usually mild and last for 2-7 days. 
      Fever
      Skin Rashes
      Conjunctivitis
      Muscle & Joint Pain
      Malaise
     Headache
There is no vaccine available for ZVD. 
Only symptomatic treatment is the 
option:
      Patient must take rest.
      Drink plenty of water and uids.
      For pain and fever OTC medicines 
     can be used.
 Avoid travelling to high risk 
countries like Brazil, France, etc.
 Use mosquito repellant and 
cover whole body to avoid mosquito 
bite.
 Don't store stagnant water.
Suspected areas women are advised 
to avoid pregnancy until the spread 
of disease is controlled.
Zika Virus Disease (ZVD) – An Emerging Culprit
Dr. Jabeen Sultana- Trainee Pharmacist
Late in January 2016, Emergency Operations Centers (EOC) were activated by CDC in respond to outbreaks of Zika , increased 
number of birth defects and reported Guillain-Barré syndrome in areas affected by Zika . Public Health Emergency of 
International Concern was declared by World Health Organization on February 1st, 2016.  The Zika outbreaks have been 
previously reported in 2007 (YAP) and 2013 (French Polynesia). Recently in 2015, the outbreak began from Brazil and 
subsequently spread to other countries in South America, Central America, and the Caribbean. However, there is no death reported 
from it.
Zika Virus is an emerging mosquito-borne virus that belongs to avivirus genre and is transmitted by Aedes aegypti mosquito. It 
was identied in Uganda in 1947 in Rh monkeys then in human in 1952 in Uganda & Tanzania. Female mosquito breed and lays 
sporadic virus eggs which can survive for one year without water and can develop into larvae in stagnant water within 3 days. The 
disease is conrmed through presence of Zika virus RNA in the blood or other body uids, such as urine or saliva.In latest report of 
WHO,  it is stated that Zika virus can be cause of increase of Guillain-Barré syndrome GBS in which the body's immune system 
attacks any part of nervous system and causes gradual weakness in the legs, arms and upper body , also sometimes leads to 
complete paralysis. It is suspected that it can be cause of increase microcephaly babies in northeast Brazil. However, more ndings 
are needed to link between zika virus and microcephaly in new born. 
DEMENTIA
RENAL DISEASE eGFR <30 ML/MIN
For behavioral complications of dementia - When non-pharmacological approaches 
have failed , Patients may be dangerous to self or others, low-dose non-
anticholinergic agent (e.g., risperidone, quetiapine) for shortest duration possible 
may be acceptable
For depression—SSRI, SNRI, bupropion. For neuropathic pain—SNRI, capsaicin 
topical, gabapentin, pregabalin, lidocaine patch
Proton pump inhibitors
For allergy—second-generation antihistamine, nasal steroid
For Parkinson disease—levodopa with carbidopa
For anxiety—buspirone, SSRI, SNRI
Antipsychotics
Tricyclic antidepressants (tertiary 
and secondary)
H2 Blocker
Anticholinergics
Benzodiazepines
For pain—acetaminophen, SNRI, topical capsaicin, lidocaine patchAll non-aspirin NSAIDs 
(including COX II)
eGFR = estimated glomerular ltration rate; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin norepinephrine reuptake inhibitor.
For Schizophrenia - Non-anticholinergic agents may be acceptable (not 
chlorpromazine, loxapine, olanzapine, perphenazine, triuoperazine, thioridazine)
For behavioral complications of dementia—if non-pharmacological approaches 
have failed and psychosis and danger to self or others, low-dose 
nonanticholinergic agent (e.g., risperidone, quetiapine) for shortest duration 
possible may be acceptable
DISEASES & POTENTIALLY 
HARMFUL DRUGS
ALTERNATIVES
Antipsychotics
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4Emerging Avenues for Botulinium Toxin Therapy
Dr. Hira Jawed –Trainee Pharmacist
Botulinum toxin A (BoNT-A), merely the single exotoxin from the 8 serotypes released by 
Clostridium Botulinum, has gained much acclaim for its neurotransmitter blocking activity. It 
basically blocks acetylcholine (Ach) release at the neuromuscular junction resulting in 
muscular paralysis. Such characteristic activity has peaked keen interest, especially in the 
minds of researchers, for the therapeutic management of anomalous functioning of glands (A 
Münchau, 2000), achalasia, myofascial pain syndrome and disorders of ocular motility (like 
nystagmus). Conventionally, Botulinum toxin is used either for the cosmetic purposes or the treatment of conditions associated 
with over activity of muscles. However, recent advancements in the eld of chemodenervation paved ways for BoNT-A use in the 
unconventional therapies. 
ADVANCEMENT IN PHARMACOTHERAPY
RECENT ADVANCEMENTS & APPLICATIONS OF BOTULINIUM TOXIN
 According to a randomized, placebo-controlled trial a low dose 
of produced a marked effect as compared to administration of 
higher dose.
It is a favorable substitute for surgical sphincterotomy in the 
treatment of anal ssures. Employment of this “Chemical 
Sphincterotomy” has the advantage of hastier ssure healing and 
signicant pain relief in comparison to GTN topical application.
Studies have shown that mean pain intensity was reduced by 60-
10% within a month of injecting BoNT-A in adults. Although, 
this indication is still understudy and it promises a safer recourse 
to neurosurgical interventions (Yong Hu, 2013)
MIGRAINE 
PROPHYLAXIS
CHEMICAL 
SPHINCTEROTOMY
TRIGEMINAL 
NEURALGIA
Injected pericranially
Injected into the internal 
anal sphincter
Hurdles that deter the frequent therapeutic use of this toxin include:
Ÿ  Treatment failure owing to the risks of denatured toxin use and erroneous injection techniques. 
Ÿ  The cost of therapy 
Ÿ  The potential of developing neutralizing antibodies due to prior exposure to the toxin 
These factors outweigh the prospective advantage in opting for BoNT-A instead of other alternates (D Dressler, 2007). Indeed it is 
not a cost effective approach but, with the proper use it could yield benecial effects in multitudinous therapies, creating newer 
vistas for unexplored indications.
Novel Treatment Approach for Pancreatic Cancer
Dr. Zarish Fatima –Trainee Pharmacist
On 22nd of October 2015, FDA approved Nano liposomal Irinotecan (Brand NAPOLI-
1). NAPOLI-1 is used along uorouracil and leucovorin to treat advanced (metastatic) 
pancreatic cancer in those patients who had treatment failure with gemcitabine-based 
chemotherapy.
Pancreatic Cancer is difcult to treat as its symptoms appear in its last stages resulting 
in survival of about 1 in 4 patients after one year diagnosis. Surgery cannot be carried 
out in patients once the disease is spread to other body parts; in such condition 
chemotherapy becomes the primary treatment. 
Effectiveness of NAPOLI-1 was demonstrated through an open-label study of 417 patients whose cancer had grown after 
receiving gemcitabine based therapy. These patients when treated with NAPOLI-1 plus uorouracil/leucovorin lived for an 
average of 6.1 months and had delay in the amount of tumor growth; while patients treated only with uorouracil/leucovorin lived 
for an average of t 4.2 months. That is why NAPOL-1 is not approved to be used as a single agent for the treatment. Additionally, 
there was no difference in the survival rate between the two treatment protocols.  Furthermore, the drug carries a black box 
warning of diarrhea and severe neutropenia.
52015 UPDATES IN A NUTSHELL
Risk Evaluation and Mitigation Strategy (REMS) is no longer 
necessary to ensure that the benets of rosiglitazone (Anti diabetic) 
medicines outweigh their risks. 
Long-term antiplatelet therapy with clopidogrel and aspirin (or aspirin 
alone) does not change the risk of death when compared to short-term 
(≤ 6 months). There is no apparent increase in the risks of cancer-related 
deaths or cancer-related adverse events with long-term treatment either.
Kayexalate binds to other medications administered by mouth. To 
avoid this potential risk, keep a gap of 6 hours for other prescribed (PO) 
or OTC (PO) medications.
FDA is investigating the adverse effect of slowed or difcult breathing 
with the use of tramadol in children aged 17 years and younger.
Changes in the requirement of monitoring, prescribing, dispensing, and 
receiving the schizophrenia medicine clozapine are being made.
It is reported that deposits of GBCAs gadolinium-based contrast agents 
remain in the brains of some patients who undergo four or more contrast 
MRI scans. However it is unknown that these deposits are harmful or 
not.
Diazoxide used for low blood sugar in infants and new born causes 
pulmonary hypertension.
NSAID's increases the chances of Strokes and Heart attacks
Use of codeine containing medicines in children under 18 years causes 
serious side effects, including slowed or difcult breathing, especially 
in those children who already have breathing problems.
A warning that serious slowing of the heart rate can occur when the 
antiarrhythmic drug amiodarone is taken together with either the 
hepatitis C drug ledipasvir and sofosbuvir or sofosbuvir taken in 
combination with another direct acting antiviral for the treatment of 
hepatitis C infection.
A study was undertaken to determine the cause of elevated levels of the 
injectable schizophrenia drug (olanzapine pamoate) in two patients 
who died.
A warning that the prescription smoking cessation medicine varenicline 
showed potential alcohol interaction, rare risk of seizures, and effects 
on mood, behavior, or thinking.
FDA cautions about using testosterone products for low testosterone 
due to aging;  increases the  risk of heart attack and stroke
Pens for injectable diabetes medicines should never be shared among 
patients, even if the needle is changed. Sharing pens can result in the 
spread of serious infections for that FDA announced that it is requiring 
additional label warnings prohibiting sharing of these injectable 
medicines.
FDA has reviewed possible risks of pain medicine use during 
pregnancy .Severe and persistent pain that is not effectively treated 
during pregnancy can result in depression, anxiety, and high blood 
pressure in the mother.
FDA Podcast 2015
Dr. Rushna Mohsin –Trainee Pharmacist
FDA PODCASTDRUGDATES. NO
Rosiglitazone
Clopidogrel
Sodium polystyrene 
sulfonate
Tramadol
Clozapine
Gadolinium Based 
Contrast Agents
Diazoxide
Non-aspirin NSAID's
Codein
Amiodarone
Olanzapine
Varenicline
Testosterone
Multi-dose 
Diabetes pen
NSAIDs, opioids, and 
acetaminophen
Dec 16
Nov 6
Oct 22
Sep 21
Sep 15
July 27
July 16
July 9
July 1
March 24
March 23
March 9
March 3
Feb 25
Jan 9
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
* For further information view the following website www.fda.gov/drugs/drugsafety/drugsafetypodcasts
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7METHOD III: 
Reporting of ADR :
Sadaf Gul , Pharmacist
WHO denes adverse drugs reaction as “A response to a drug which is noxious, unintended, and which occurs at doses normally 
used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modications of physiological function.”
 It's a responsibility of every health care professional and all those taking medicines to report any untoward reaction of a drug. 
Reporting of adverse drug reactions help us with continous monitoring for trends of ADRs  and develop strategies to prevent any 
complications in the future.  It also help us assess the quality of pharmaceutical care and safety of drug therapies, especially 
recently approved drugs. On the basis of these trends different educational programs for healthcare professionals and patients can 
be planned.  Reporting of ADR will not only benet the Pharmacovigilance department but will also reduce the hospitalization of 
patient and minimize the liability of our hospital. 
Remember “little drops of water make the mighty ocean”, every little effort made to improve reporting or spreading awareness 
about ADRs will make a difference. In our hospital adverse drug reactions can be reported through following three methods 
(External customers may call Drug and Poison Information Center at 021-34861477 to report an ADR).
METHOD I: YELLOW CARDS
METHOD II: ONLINE REPORTING FORM
Have patients MR # and brief description of ADR handy at the time of calling!
ADR Trends at AKUH 2015
Figure 1: Pharmacological Categories Figure 2: ADRs reported per Month
Figure 3:  Reporting Areas Figure 4:  Patients and Professionals 
who reported the ADR.
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Ask Away!
You may get an experts opinion by consulting with one of our or pharmacists. Send in your questions at drug.information@aku.edu
OUR PANEL: 
Kashif Hussain, Infectious Disease Specialist
Nadia Ayoub, Oncology Pharmacy Specialist
Pharmacists at DPIC
Provide us your Valuable Feedback!
LINK: https://docs.google.com/forms/d/1IAduMbPm_X9yP9lN-OvpdYEEQLWFycho4U6uQWXet3c/edit#
The feedback form can be emailed to you as well. Just drops us an email with the Subject Newsletter Feedback
Email us at: drug.information@aku.edu
Drug and Poison Information Center maintains the record of all adverse drug reactions reported in the hospital through yellow 
card, online ADR form, hotline service or trigger & marker activity.  This data is then reviewed by Pharmacy and Therapeutic 
Committee and necessary measures are taken for patient safety. In 2015, total 139 ADRs were reported at Aga Khan University 
Hospital.  Majority of the ADRs were reported by pharmacists and most commonly reported ADRs were of antimicrobials. 
